Avalyn Pharma has initiated a Phase 1b clinical trial to test AP02, a therapeutic candidate for pulmonary fibrosis (PF), in adult healthy volunteers. The placebo-controlled trial of inhaled nintedanib will assess its safety, tolerability, and pharmacological profile when given at single or multiple ascending doses. Its main goal…
Phase 1b trial launched of inhaled nintedanib for pulmonary fibrosis
Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease, which means it worsens over time. Because there’s no cure, the goal is to try and preserve lung function for as long as possible. This may involve regular monitoring and other measures, such as pulmonary function testing, exercise,…
Last week, I participated in one of the most unique speaking opportunities I’ve had on my journey with pulmonary fibrosis. I was asked to provide a patient’s perspective to a caregiver support group. When I was diagnosed with idiopathic pulmonary fibrosis (IPF) in January 2017, it caught…
Living in Texas means facing an unpredictable climate. One minute, the skies are blue and it’s sunny, and the next, thunderstorms and tornadoes are rolling in without warning. I’ve lived in Texas all my life and still can’t keep up with the changes. Having pulmonary fibrosis (PF) doesn’t make…
Reviva Pharmaceuticals has been awarded a U.S. patent covering the use of its experimental therapy brilaroxazine in treating people with pulmonary fibrosis. The patent, No. 12053477, granted by the U.S. Patent and Trademark Office specifically covers the use of brilaroxazine in idiopathic pulmonary fibrosis (IPF), as well…
Looking at the person sitting nearby, I’ll often say, “So what are you in for?” While to me the question is slightly reminiscent of a conversation between two inmates, that’s not the case in this example. This conversation starter also works at a transplant clinic. I was diagnosed with…
Brainomix, a U.K.-based software company, has joined forces with Boehringer Ingelheim, a German pharmaceutical company, to accelerate the diagnosis of pulmonary fibrosis (PF) in the U.S. and improve treatment access for people with scarring of the lungs. As part of the collaboration, Brainomix’s artificial intelligence (AI)-powered tool, called Brainomix 360…
Living with a rare disease is expensive. While I agree with the cliches that “money can’t buy happiness” and “time is more valuable than money,” the limited financial aid available to patients stresses me out. When I was diagnosed with idiopathic pulmonary fibrosis (IPF) in 2016, I wasn’t thinking…
A Newsweek article from a few weeks ago was headlined, “Washington, D.C., Endures Most Blistering Heat Wave in Nearly 100 Years.” As I write this, another article, this one from The Washington Post, just dropped, warning that “D.C. area begins fifth heat wave amid one of its…
Enrollment has been completed for a Phase 2a study that’s testing idiopathic pulmonary fibrosis (IPF) treatment BBT-877, an investigational therapy from Bridge Biotherapeutics. The Phase 2a trial (NCT05483907) is evaluating the safety, tolerability, and efficacy of BBT-877 in 120 adults with IPF, ages 40 and older, with or…
